Nico Gagelmann, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, provides an outlook on the current CAR-T climate for multiple myeloma, and where things might move in the future, including longer follow up, new targets, as well as allogeneic CAR T-cell approaches. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

свернуть